Skip to main content
✕

Packaged solution

One roadmap from early development to a confident launch.

Life sciences consulting that gives pharmaceutical and biotech teams a standardized, integrated roadmap, so every function works to the same milestones.

Talk to our experts
Format One standardized roadmap across your cross-functional teams
Led by Senior industry experts
Answers How do we move from development to a predictable, successful launch?

Overview

What is a product development roadmap?

  • A product development roadmap is a single, integrated plan that shows how a product moves from early development to commercial launch. It lays out milestones, stage gates, deliverables, dependencies, and owners across every function, giving teams one shared view of the critical path so decisions and handoffs happen on time.
  • The Kryus Product Development Roadmap helps pharmaceutical, biotechnology, and life sciences organizations build a standardized Product Development Roadmap (PDR) that connects strategy, clinical, CMC, regulatory, manufacturing, supply chain, quality, and commercial teams. Our life sciences consulting team builds the structure and leads the alignment. Your experts keep the science.
  • The result is stronger cross-functional alignment, more predictable execution, and lower development and commercialization risk. We pair new product development consulting with pharmaceutical project management and a clear milestone plan, whether the work is biotech consulting for an emerging company or support for an established portfolio.

What is CMC in drug development?

CMC stands for chemistry, manufacturing, and controls. It covers how a drug is made, tested, and kept consistent in quality, from early batches through commercial production. CMC strategy shapes timelines, because manufacturing readiness, scale-up, and process validation all have to be in place before launch.

Kryus does not replace your CMC experts. As a life sciences consultancy, our role is to connect CMC to the rest of the roadmap. We work alongside your teams, your CDMO and other life science service providers, and any CMC consulting partners you use, so external manufacturing timelines support the launch plan.

Why do pharmaceutical product launches fail?

Most launch problems start long before launch. Functions plan in isolation, critical dependencies surface late, and decision rights are unclear. Manufacturing, supply, quality, and commercial teams may not be ready when the regulatory timeline says they must be. Treating launch readiness as a late-stage task leaves little room to recover.

Common causes include:

  • Cross-functional alignment that fades after the kickoff meeting
  • Hidden dependencies between clinical, CMC, regulatory, and supply plans
  • Unclear go / no-go decision criteria at stage gates
  • Commercial readiness and the launch supply plan started too late
  • Execution risk that nobody owns or tracks

Fixing this takes both strategy and execution. Our life sciences strategy consulting links product strategy to operational readiness from the start, so problems are found while there is still time to solve them.

Services included

Four services. One focused engagement.

Kryus brings more than 26 years of experience to this work. As a life sciences consulting firm, we draw on the four service areas below. Unlike many pharmaceutical consulting firms, we work alongside your teams through execution.

What we cover

What are the stages of the drug development process?

The drug development process runs from discovery and preclinical research through three clinical phases, regulatory review, and post-approval monitoring, with launch preparation alongside. A shared roadmap links each stage, so every function can see what the next one needs from them.

01

Discovery and preclinical

The roadmap starts here, with the product's intended profile and an integrated development plan that sets direction before costs rise.

02

Early clinical (Phases 1 and 2)

A clinical development plan, early CMC planning, and clear milestones keep clinical operations and manufacturing in step through each phase transition.

03

Late-stage clinical (Phase 3)

Tech transfer pharma activities, validation work, and supply plans line up with trial timing, so late-stage readiness does not hold up the whole program.

04

Regulatory review

Regulatory affairs, quality systems, and GMP readiness are tracked on the same plan as submission milestones.

05

Launch preparation

Pharma launch readiness work brings commercial, supply, and quality teams together on one launch sequence, with commercial launch readiness checks before go-live.

06

Post-approval and lifecycle

Lessons from each launch feed back into the standard roadmap, with program assurance so the approach keeps improving.

Our approach

From strategy to launch.

  1. 1

    Assess and align

    Our life sciences consulting team reviews how each function plans today, finds the gaps and overlaps, and aligns leadership on a common operating framework.

  2. 2

    Build the roadmap

    We define stage gates, deliverables, and milestones, with clear owners and an accountability model for each.

  3. 3

    Integrate

    We link the plans across functions, identify critical dependencies, and set the governance cadence for reviews and decisions.

  4. 4

    Embed and scale

    We help teams use the roadmap on live programs, then standardize it so it repeats across the portfolio. This is where life sciences consulting support matters most.

What you receive

Deliverables

  • Standardized Product Development Roadmap (PDR) template and the process to use it
  • Defined stage gates, deliverables, and go / no-go criteria
  • Governance model and ownership across functions
  • Integrated plan showing critical dependencies and risks
  • A launch excellence framework linking development, supply, quality, and commercial plans

The impact

The results we aim for

Stronger alignment across functions
Faster progress to milestones
More predictable execution
Lower development and commercialization risk
Better launch readiness
A repeatable, scalable approach
FAQ

Common questions

A stage gate process divides development into phases separated by formal decision points called gates. At each gate, leaders review defined deliverables and evidence, then decide to proceed, pause, or stop. Clear criteria keep decisions consistent and tie investment to progress. The Roadmap defines the gates, criteria, and who decides, across functions.
A target product profile summarizes the intended characteristics of a product, such as its indication, dosing, and key claims. It guides development decisions and is revisited as evidence builds. Because it defines the destination, it also anchors the roadmap that every function plans against.
Launch readiness is the state of being fully prepared to bring an approved product to market. It covers regulatory approval, manufacturing and supply, quality, and commercial capabilities, all ready at the same time. Product launch readiness works best when it is planned alongside development, not added at the end.
Bringing a new drug to market often takes ten years or more from discovery to approval, and timelines vary by product and therapeutic area. Clinical trials account for much of that time. A standardized roadmap cannot shorten the science, but good life sciences consulting can protect speed to market by reducing avoidable delays between functions.
An integrated product development plan combines the plans for strategy, clinical, CMC, regulatory, manufacturing, supply chain, quality, and commercial work into one schedule. It shows dependencies and the critical path in one place. This approach lets teams see conflicts early and resolve them before they cost time.
Product development is the work of discovering, testing, and gaining approval for a product. Commercialization is the work of bringing it to patients: manufacturing at scale, supply, market access, and sales. The two overlap heavily, so commercialization strategy should take shape during development, not after. Good life sciences consulting treats them as one plan.
Give them one plan, one set of milestones, and clear ownership. Shared stage gates and a regular cadence surface conflicts early. As part of our life science advisory work, Kryus leads that alignment alongside your own experts and any regulatory strategy consulting or drug development consulting partners, so each function sees what the others need.

Case study

See what an engagement looks like.

Download a case study to see how Kryus brings life science consulting and execution support from development through launch.

What clients say

In their words.

"What impressed us most was Kryus Ventures' ability to bridge strategy and execution. Their resilience framework, governance model, and business continuity planning created sustainable capabilities that continue to deliver value."
Head of Global Operations Excellence
Head of Global Operations Excellence
Pharmaceutical Mfg Company
"What differentiated Kryus was combining procurement expertise, operational excellence, and digital enablement into a single transformation program. Their collaborative approach embedded improvements that we still rely on today."
Senior Director, Strategic Sourcing & Procurement
Senior Director, Strategic Sourcing & Procurement
Fortune 500 Company
"Kryus Ventures helped us identify opportunities we could not see due to fragmented data and decentralized operations. The resulting improvements in cost, supplier reliability, and stakeholder satisfaction exceeded our expectations."
Executive Sponsor
Executive Sponsor
Enterprise Transformation Initiative

Your next step

Let's talk about getting your product from development to launch.

Tell us where your development or launch plans are getting stuck. A senior partner will walk through how this life sciences consulting engagement would apply to your programs.

  • Talk directly with a senior partner
  • Learn how the Roadmap would be scoped for you
  • No obligation
Book a scoping call